Study Shows ATP Improves Motility of Sperm From Infertile Males

LA JOLLA, Calif., Feb. 7, 2008 (PRIME NEWSWIRE) -- Duska Therapeutics, Inc.
(OTCBB:DSKA), a biopharmaceutical company developing diagnostic and therapeutic
products based on adenosine 5'-triphosphate (ATP) and P2 receptor-related
technologies, announced today that the results of a study sponsored by the
company and published in the journal of Reproductive Sciences shows the motility
of human sperm is enhanced by extracellular ATP. (Scott E. Edwards, et al.,
"Effects of Extracellular Adenosine 5'-Triphosphate on Human Sperm Motility,"
2007; 14: 655-666).

"We are very pleased with the clear outcome of this study, which was carried out
in leading academic centers in the U.S. and Europe," said Dr. Amir Pelleg,
Duska's President and Chief Scientific Officer. "We believe that these data
strengthen the rationale for the development of ATPotent(tm), which contains
ATP, as a novel, sperm motility enhancement medium in conjunction with in vitro
fertilization (IVF) and intrauterine insemination (IUI)," he added.

The study, conducted by scientists from the Center for Research on Reproduction
and Women's Health of the University of Pennsylvania and the Department of
Medical and Surgical Sciences of the University of Padova, Italy, showed that
ATP treatment of poorly motile human sperm in vitro (outside of the human body)
resulted in improved motility parameters and increased frequency of
hyperactivated sperm. Furthermore, improved motility parameters were also
observed in human sperm derived from males with asthenozoospermia (a disorder
characterized by lack of or low sperm motility), and human sperm from
cryopreservation.

The authors suggested that these effects of ATP could explain the increased
success rate of in vitro fertilization (IVF) procedures observed in an earlier
non-Duska sponsored European study, in which ATP-treated sperm derived from
infertile males with asthenozoospermia were used.

In this Duska-sponsored study, no human embryos were created or destroyed.

About Male Infertility and ATPotent(tm)

Asthenozoospermia, that is, lack of or low sperm motility, is a common cause of
human male infertility. It has been reported in the medical literature that the
prevalence of asthenozoospermia in infertile men is approximately 82 percent.
Currently, there is no FDA-approved product that improves sperm motility.
Duska's proprietary ATPotent(tm) is being developed as a sperm processing medium
to improve sperm motility in conjunction with IVF and IUI procedures. One
component of ATPotent(tm) is ATP, a naturally occurring biological molecule that
is found in all human cells. Naturally occurring ATP in the female reproductive
tract is believed to play a facilitating role in normal egg fertilization.
Several in vitro studies conducted on sperm of human and other species suggest
that ATP treatment of poorly motile sperm resulted in improved motility
parameters and increased frequency of hyperactivated sperm.

About Duska Therapeutics, Inc.

Duska Therapeutics focuses on the development of therapeutic and diagnostic
products related to adenosine 5'-triphosphate (ATP), and cell-surface P2
receptors (P2R). Duska owns or has exclusive license rights to a number of
proprietary diagnostic and therapeutic applications, four of which are currently
in various stages of development in the fields of cardiac arrhythmias, male
infertility, chronic obstructive pulmonary disorders and cough, and glaucoma.
For more information, visit Duska's website at www.duskatherapeutics.com.

Forward-looking statements

This press release may contain forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, that involve
risks and uncertainties that could cause actual events or results to differ
materially from the events or results described in the forward-looking
statements, The forward-looking statements are based on current expectations,
estimates and projections made by management. Duska intends for the
forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements. Words such as "anticipates," "expects," "intends,"
"plans," "believes'' "seeks," "estimates," or variations of such words are
intended to identify such forward-looking statements. All statements in this
release regarding the future outlook related to Duska, including beliefs as to
the benefits of this sponsored study are forward-looking statements. Additional
uncertainties and risks are described in Duska's most recently filed SEC
documents, such as its most recent annual report on Form 10-KSB, all quarterly
reports on Form 10-QSB and any current reports on Form 8-K filed since the date
of the last Form 10-KSB. Copies of these filings are available through the SEC
website at www.sec.gov. All forward-looking statements are based upon
information available to Duska on the date hereof. Duska undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.

-0-
CONTACT: Duska Therapeutics, Inc.
James S. Kuo, M.D., M.B.A., Chairman and CEO
858.551.5700
Fax: 858.551.5704
kuoj@duskatherapeutics.com
470 Nautilus Street, Suite 300
La Jolla, CA 92037